Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2021 07:00 ET | Source: Kamada Ltd.

Kamada Files Annual Report for the Year Ended December 31, 2020

REHOVOT, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F...
February 10, 2021 07:00 ET | Source: Kamada Ltd.

Kamada Reports Fourth Quarter and Fiscal Year 2020 Financial Results, Recent Achievements and Corporate Development Activities

Full-Year 2020 Revenues were $133.2 Million, In-Line with the Company’s Guidance; Adjusted EBITDA for 2020 was $25.1 MillionKamada Enters U.S. Plasma Collection Market Through Acquisition of an...
February 03, 2021 07:00 ET | Source: Kamada Ltd.

Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2020 Financial Results, and Host Conference Call on February 10, 2021

REHOVOT, Israel, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
February 01, 2021 07:00 ET | Source: Kamada Ltd.

Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA

Transaction Represents Kamada’s Entry into U.S. Plasma Collection Market and Advances the Company’s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company Blood and Plasma...
January 13, 2021 07:00 ET | Source: Kamada Ltd.

Kamada Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel

The Three Products Are Expected to Be Launched, Subject to Israeli Ministry of Health Approval, Between 2022 and 2024Potential Collective Maximum Sales of the Three Products in the Israeli Market is...
January 05, 2021 07:00 ET | Source: Kamada Ltd.

Kamada Selected as a Winner of the Genesis Prize Foundation and Start-Up Nation Central Competition

REHOVOT, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it has been selected as one of 10 winners of...
December 21, 2020 07:00 ET | Source: Kamada Ltd.

Kamada Added to the NASDAQ Biotechnology Index

REHOVOT, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to...
November 11, 2020 07:00 ET | Source: Kamada Ltd.

Kamada Reports Third Quarter and First Nine Months of 2020 Financial Results, Recent Achievements and Corporate Development

Third Quarter and First Nine Months of 2020 Revenues were $35.3 million and $101.7 million Respectively, a 7% Increase Compared to Both 2019 Periods; Company Reiterates Full-Year 2020 Total Revenue...
November 04, 2020 07:00 ET | Source: Kamada Ltd.

Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020

REHOVOT, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
October 19, 2020 07:00 ET | Source: Kamada Ltd.

Kamada Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021

Treatment with Kamada’s Investigational IgG Product Will Be Regulated by the Israeli Ministry of HealthInitial Order Sufficient to Treat 500 Patients Positive Interim Safety and Symptoms Improvement...